Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pradigastat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 known ✓ | O75907 | 19/20 | 1.00 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pradigastat SCHEMBL180536 | 1.00 | DGAT1 (1.00) | DGAT1SOAT1 | |
| Pradigastat SCHEMBL16104874 | 1.00 | DGAT1 (1.00) | DGAT1SOAT1 | |
| Pradigastat SCHEMBL29358725 | 1.00 | DGAT1 (1.00) | DGAT1SOAT1 | |
| Pradigastat SCHEMBL29434818 | 0.91 | DGAT1 (0.84) | DGAT1 | |
| SCHEMBL15131446 | 0.91 | DGAT1 (0.84) | DGAT1 | |
| Pradigastat SCHEMBL29516945 | 0.91 | DGAT1 (0.84) | DGAT1 | |
| SCHEMBL15445225 | 0.91 | DGAT1 (0.82) | DGAT1SOAT1 | |
| SCHEMBL180809 | 0.91 | DGAT1 (0.82) | DGAT1SOAT1 | |
| SCHEMBL13664086 | 0.91 | DGAT1 (0.82) | DGAT1SOAT1 | |
| SCHEMBL31326545 | 0.91 | DGAT1 (0.82) | DGAT1SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11304907-B2 | Pharmaceutical compositions containing a DGAT1 inhibitor | NOVARTIS AG (CH) | 2022-04-19 | — | — | US | claimed |
| CN-111936137-A | Compositions and methods for treating severe constipation | 安济药业公司 | 2020-11-13 | — | — | CN | claimed |
| US-20200230062-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR | NOVARTIS AG (CH) | 2020-07-23 | — | — | US | claimed |
| US-10646446-B2 | Pharmaceutical compositions containing a DGAT1 inhibitor | NOVARTIS AG (CH) | 2020-05-12 | — | — | US | claimed |
| EP-2627319-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR | NOVARTIS AG (CH) | 2018-11-21 | — | — | EP | claimed |
| US-20180243222-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR | NOVARTIS AG (CH) | 2018-08-30 | — | — | US | claimed |
| US-20160374947-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR | NOVARTIS AG (CH) | 2016-12-29 | — | — | US | claimed |
| EP-2552441-B1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2016-05-04 | — | — | EP | claimed |
| US-20150320687-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR | NOVARTIS AG (CH) | 2015-11-12 | — | — | US | claimed |
| US-11819495-B2 | Compositions and methods for treating severe constipation | ANJI PHARMACEUTICALS INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220193044-A1 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | SERLEVA, INC. | 2022-06-23 | — | — | US | disclosed |
| US-20220160897-A1 | Method for Stimulating Axonal Regeneration | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2022-05-26 | — | — | US | disclosed |
| US-11304907-B2 | Pharmaceutical compositions containing a DGAT1 inhibitor | NOVARTIS AG (CH) | 2022-04-19 | — | — | US | disclosed |
| US-11304907-B2 | Pharmaceutical compositions containing a DGAT1 inhibitor | NOVARTIS AG (CH) | 2022-04-19 | — | — | US | disclosed |
| US-20130018074-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
| CN-102834099-A | Uses of DGAT1 inhibitors | NOVARTIS AG | 2012-12-19 | — | — | CN | disclosed |
| WO-2012051488-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR | NOVARTIS AG (CH) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012047948-A1 | NEW CRYSTALLINE FORMS OF THE SODIUM SALT OF (4- {4- [5- ( 6 - TRIFLUOROMETHYL - PYRIDIN- 3 - YLAMINO ) - PYRIDIN- 2 -YL] -PHENYL} - CYCLOHEXYL) -ACETIC ACID | NOVARTIS AG (CH) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012047948-A1 | NEW CRYSTALLINE FORMS OF THE SODIUM SALT OF (4- {4- [5- ( 6 - TRIFLUOROMETHYL - PYRIDIN- 3 - YLAMINO ) - PYRIDIN- 2 -YL] -PHENYL} - CYCLOHEXYL) -ACETIC ACID | NOVARTIS AG (CH) | 2012-04-12 | — | — | WO | disclosed |
| WO-2011123401-A1 | USES OF DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819495-B2 | Compositions and methods for treating severe constipation | DGAT1, DGAT2, LCAT | DGAT1 1/4885SOAT1 6/4885 |
| US-20160374947-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR | DGAT1, DGAT2, MGAT1 | DGAT1 1/4885SOAT1 4/4885 |
| US-20180243222-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR | DGAT1, DGAT2, MGAT1 | DGAT1 1/4885SOAT1 4/4885 |
| US-20150320687-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR | DGAT1, DGAT2, MGAT1 | DGAT1 1/4885SOAT1 4/4885 |
| US-10646446-B2 | Pharmaceutical compositions containing a DGAT1 inhibitor | DGAT1, DGAT2, MGAT1 | DGAT1 1/4885SOAT1 4/4885 |
| US-11304907-B2 | Pharmaceutical compositions containing a DGAT1 inhibitor | DGAT1, DGAT2, MGAT1 | DGAT1 1/4885SOAT1 4/4885 |
| US-20200230062-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR | DGAT1, DGAT2, MGAT1 | DGAT1 1/4885SOAT1 4/4885 |
| US-20220160897-A1 | Method for Stimulating Axonal Regeneration | LYPLA1, LPCAT1, SPTLC1 | DGAT1 6/4885SOAT1 24/4885 |
| US-20220193044-A1 | COMPOSITIONS AND METHODS FOR TREATING SEVERE CONSTIPATION | DGAT1, DGAT2, LCAT | DGAT1 1/4885SOAT1 6/4885 |
| US-20130018074-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885SOAT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.